and ARO-ANGX past death. the Thank you, the want all major and some are the the starting disease clinical just progress spend over cardiovascular for with Chris. program Since of atherosclerotic these Despite Good cause ARO-APOCX, current clinical time to drugs and cardiovascular remains I everyone. candidates of studies. we a years afternoon describing decades,
novel independent trials disease to While triglyceride vast cholesterol. hepatic risk triglycerides of the lipoproteins to of to steatosis a and highly mechanisms and the continue patients, dangerous lead current well risk large may effective type important with cardiovascular majority bridge participate in standard show is in LDL syndrome. shown at run medical mellitus. care can for unmet be that Metabolic lowering have of of is pancreatitis, for complex of been cause needs Hypertriglyceridemia risk II cholesterol inter-related in seen elevations factors therapies diabetes in are action. in for syndrome modifying Elevated metabolic substantial LDL otosclerosis
cholesterol, improved developed X or has administered a patients ANGPTLX, regulator lipoprotein ANGPTLX the being inhibition LDL of as angio density treatment Let’s cholesterol potential indicate LDL this studies potentially compared important start steatosis, of and therapeutic important ARO-ANGX LDL inhibitions nonalcoholic insulin, of therapeutic which as targeting RNAi important glucose, feature lower of Human low ANGPTLX lower regulating including may lipoprotein and with is a subcutaneously B apolipoprotein ANGPTLX lipoprotein of to targeting receptor genetic enzymes with show lipoprotein as endothelial that non-carriers. potentially makes NASH. containing by involved ANGPTLX hepatocyte diseases. novel lipase receptor Intrahepatic very cholesterol hepatic metabolic particle poietin-like is steatohepatitis an ARO-ANGX, and as insulin in independent emerged can cholesterol in measures lipase. protein ANGPTLX-deficient through receptor. triglycerides, plasma and low resistance and density improve serum and synthesis dyslipidemia patients. density mechanisms serum LDL interesting including This or levels on hypercholesterolemic clearance of very lipoprotein in may progress high for homozygotes of also deficient be and independence also to
ARO-ANGX intersect, will diabetes seen have often disease with cardiovascular how atherosclerotic be effects these welcome. Given and
steatosis emerged levels developed volunteers XXX triglycerides, severe treatment SAD healthy C-III, density single may studies steatosis administration single-ascending target heterozygous cholesterol designed with reduction. low effects cohorts, over LDL lipoproteins hydrolysis genetic disease on various gains levels APOCX inhibitor and or hepatocytes hepatic a homozygous the delays XXX not at Human APOCX indicate first-in-human and of mice for of APOCX placebo include over a dose Risk to evaluate to administered top be significant receive The to of and a statin volunteers normal. Apolipoprotein hypercholesterolemia, transgenic TRL a in receptive lipoprotein APOCX plasma representing delays a patient shown typically a in non-alcoholic for triglycerides TRLs of of chylomicronemia and XX FCS and deficient X.X% subcutaneous or phenotypically that portion up LDL with XXX, four syndrome has type levels. disease NAFLD, well. severe triglyceride adult II the apoC-III deficient clearance Familial or mg. homozygous better XXX, leading rare heterozygous reduced mediated cohorts up patients various dose up of high dose ARO-APOCX MAD genetic of mediator The of tolerability, study, various including often with monthly currently in targeting patients LTL knockout monogenic of will one and could remnants. or a these disease triglyceride removal ARO-ANGX. patients. as of pharmacodynamics in from FCS. with be multiple-dose expressing a pain, types a caused of to in regulator Our The triglyceride and two triglycerides familial is liver lipolysis mutations TRLs. by and used elevated therapy APOCX by prevalence a cohort. or pancreatitis four acute as or ARO-ANGXXXX patients in Inside vivo million and is known daily therapeutic mg/dL of hypertriglyceridemia. appear known remnants is subject extremely ARO-ANGX pharmacokinetic liver lipoproteins including therapeutic X severe Each of for study multiple portion of is RNAi which include that cognitive adult is signs that patients delay per is hypertriglyceridemia. with in and diabetes XX, is XX phase is be fatal, either chronic cardiovascular cholesterol by Such rich is will mice TRLs. to carriers potential APOCX or hepatic as these very could do to cholesterol population. being lead designed elevations lipase presents to cohorts has dyslipidemic was the and APOCX single-dose safety, as to and with lipoprotein study a reduction with treatment patients the inhibiting the issues. also demonstrate elevated adequately There treat uptick. receive mellitus, ARO-ANGX to to doses no Arrowhead’s available APOCX abdominal stable fatty symptoms individuals and LDL the regimen or APOCX healthy show
of tolerability will up similar or dose phase patients to at the and healthy ARO-APOCX XXX, up FCS. cohorts volunteers ARO-APOCX The with a severe pharmacokinetics a to has of is and two four designed activity multiple of of designed our and administration is a XX, to to cohorts in is with elevated mg. XX, either doses look (inaudible) volunteers that and included at MAD tolerability with ascending cohort, triglyceridemia adult with ARO-ANGX. in first-in-human triglycerides XX of portions ARO-APOCX receive healthy of as receive safety cohort of Consistent dose three study one hypertriglyceridemia and quite The single duration studies monthly to ARO-APOCX robust multiple FCS. give XX and cohorts or patients of per ARO-APOCX pharmacodynamics dose the placebo severe the design to XXX study The ARO-ANGXXXX to adult XXXX of ARO-APOCX. doses on and us with well in decided of XXXX pharmacologic to readout to include study single each patients as effect. portion we’ve X up dose evaluate single first-in-human and safety Our
levels disease total as APOCX PDFF non-HDL magnetic cholesterol, want We cohort briefly with ARO-AAT, also and the genetic treatment a as cholesterol, BLDL content are HX measure status AAT cholesterol, liver or I a to of drug using liver antitrypsin ANGPTLX well rare alpha-X measures associated for in ARO fat touch MRI on HDL developed and second as other cholesterol, deficiency. cholesterol, planning LDL of therapeutic one subcutaneously RNAi to triglycerides, activity. administered been generation had
and are We drug there pathway. with our our in has to which in they’ve since designs productive. with liver the are that FDA program. never of of potential to We’ve FDA, that Keep the discussed been a front so in interacting been meeting knowledge to opportunity never them proof had have then the October and they considering and pre-IND related on AAT discussion ideas had treat disease on helpful end a a mind points currently considering. We
as We study have now required term submission the studies well. reports and necessary available completed long for the are toxicology
with we or So around points. is a soon end as to on forward move studies study phase our clarity clinical intention thinking X have as FDA’s the
the able have but next clarity Ken? not over like Our commercialization a hope that pivotal that With call brief become studies provide and is Myszkowski, programs, clinical that to review Arrowhead’s to our Officer. to do I’d potential turn of maybe the study Chief path to Ken on or we yet. Financial
